Skip to main content
Top

Breast Cancer Research and Treatment

Issue 3/2006

Content (16 Articles)

Serum selenium measurements in women with early-stage breast cancer with and without chemotherapy-induced ovarian failure

Hollie A. Breedlove, Anne M. Smith, Raymond F. Burk, Kristina E. Hill, Charles L. Shapiro

A Cohort Study of Antihypertensive Medication Use and Breast Cancer Among Danish Women

Jon P. Fryzek, Aslak H. Poulsen, Loren Lipworth, Lars Pedersen, Mette Nørgaard, Joseph K. McLaughlin, Søren Friis

Epidemiology

Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women

George Pentheroudakis, George Fountzilas, Dimitrios Bafaloukos, Vasiliki Koutsoukou, Dimitrios Pectasides, Dimosthenis Skarlos, Epaminondas Samantas, Haralabos P. Kalofonos, Helen Gogas, Nicholas Pavlidis

Epidemiology

Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer

James J. Dignam, Kelly Wieand, Karen A. Johnson, Peter Raich, Stewart J. Anderson, Carol Somkin, D. Lawrence Wickerham

Epidemiology

Association between TP53 and p21 genetic polymorphisms and acute side effects of radiotherapy in breast cancer patients

Xiang-Lin Tan, Odilia Popanda, Christine B. Ambrosone, Silke Kropp, Irmgard Helmbold, Dietrich von Fournier, Wulf Haase, Marie Luise Sautter-Bihl, Frederik Wenz, Peter Schmezer, Jenny Chang-Claude

Preclinical study

Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells

Stephen Hiscox, Liam Morgan, Tim P. Green, Denise Barrow, Julia Gee, Robert I. Nicholson

Preclinical study

The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study

Ombretta Salvucci, Amélie Bouchard, Andrea Baccarelli, Jean Deschenes, Guido Sauter, Ronald Simon, Rosella Bianchi, Mark Basik

Clinical trial

Patients with preoperatively ultrasonically uninvolved axillary lymph nodes: a distinct subgroup of early breast cancer patients

Janez Zgajnar, Marko Hocevar, Maja Podkrajsek, Kristijana Hertl, Snjezana Frkovic-Grazio, Gaj Vidmar, Nikola Besic

Clinical trial

Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer

Brenda W. Cooper, Tomas Radivoyevitch, Beth A. Overmoyer, Robert R. Shenk, Huong T. Pham, Judith R. Samuels, Margaret P. Parry, Paula Silverman

Clinical trial

The “Sentinel Chain”: a new concept for prediction of axillary node status in breast cancer patients

Moshe Carmon, Oded Olsha, William P. Schecter, David Raveh, Constantin Reinus, Dan D. Hershko, Uziel Beller, Eliahu Golomb

Clinical trial

Expression and Clinical Signification of Cytosolic Hyaluronan Levels in Invasive Breast Cancer

María D. Corte, L.O. González, Mª Luz Lamelas, Ana Alvarez, Sara Junquera, Mª Teresa Allende, José L. García-Muñiz, Juan Argüelles, Francisco J. Vizoso

Letter to the editor

Styrene and breast cancer incidence in Texas: a comment on an ecological association

Carol J. Burns, George Cruzan, Shan P. Tsai

Letter to the Editor

Comment to Anderson WF, Jatoi I, Devesa SS: Distinct Breast Cancer Incidence and Prognostic Patterns in the NCI’s SEER Program: Suggesting a Possible Link Between Etiology and Outcome. Breast Cancer Res Treat 90:127–137, 2005

Romano Demicheli, Gianni Bonadonna, Marco Greco, William J.M. Hrushesky, Angela Moliterni, Michael W. Retsky, Pinuccia Valagussa, Milvia Zambetti

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine